Print

THERAVECTYS is Granted Authorization From the French and Belgian Regulatory Agencies to Launch a Phase I/Ii Clinical Trial for Its Anti-HIV Therapeutic Vaccine Candidate  
11/30/2012 11:46:41 AM

PARIS--(BUSINESS WIRE)--THERAVECTYS, a French biotechnology company currently developing a new generation of vaccines, today announced it was granted authorization by the National Security Agency for Medicines and Health Products in France (Agence Nationale de Sécurité du Médicament et des produits de santé) and the Federal Agency for Medicines and Health Products in Belgium (Agence Fédérale des Médicaments et des Produits de Santé) to launch a phase I/II clinical trial for its anti-HIV therapeutic vaccine candidate based on lentiviral vector technology.
//-->